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HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-
dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or
sequentially to chemotherapy, a significant disease-free and/or overall survival improvement has been observed in HER-2þ early and
MBC. Unfortunately, in both settings, trastuzumab is associated with an increased risk of cardiac dysfunction (CD). We have reviewed
the clinical charts of HER-2-overexpressing MBC patients treated with trastuzumab after HDC. Age, baseline left ventricular ejection
fraction (LVEF), radiation therapy on cardiac area, exposure to anthracycline, single or multiple transplant, high-dose agents,
trastuzumab treatment duration were recorded as potential risk factors. In total, 53 patients have been included in the analysis.
Median LVEF at baseline was 60.5%; at the end of trastuzumab (data available for 28 patients only), it was 55% (P¼0.01). Five out of
the 28 (17.9%) patients experienced CD. Two out of 53 (3.8%) patients developed a congestive heart failure. Age X50 years and
multiple transplant procedure were potential risk factors for CD. The overall incidence of CD observed in this population of HER-
2þ MBC patients treated with trastuzumab after HDC is not superior to that reported with concomitant trastuzumab and
anthracyclines. However, patients with age X50 years or receiving multiple course of HDC should be considered at risk for CD.
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High-dose chemotherapy with autologous hemopoietic progenitor
support has been compared to standard dose chemotherapy in
high-risk early breast cancer as well as in metastatic disease. In
high-risk breast cancer, there are negative trials showing no
superiority for high-dose chemotherapy (Bergh et al, 2000;
Hortobagyi et al, 2000; Tallman et al, 2003); in contrast, other
trials have shown significant improvement in relapse-free and
overall survival (Roche et al, 2003; Rodenhuis et al, 2003; Nitz et al,
2005). In metastatic breast cancer, whereas some trials have failed
to demonstrate a survival benefit, others have suggested an
advantage in event-free survival in favour of high-dose treatment
(Stadtmauer et al, 2000; Crown et al, 2004; Lotz et al, 2005; Schmid
et al, 2005). In spite of these conflicting results, it is however clear
that, at present, high-dose chemotherapy cannot be considered
standard treatment for any breast cancer patient. On the other
side, longer follow-up of the randomized trials and a meta-analysis
of their pooled data might confirm a limited advantage; moreover,
because of the reduced treatment-related mortality and availability
of new anticancer drugs, this treatment modality could still
represent a field of research for some subsets of patients.
It is now clear that breast cancer represents a very hetero-
geneous disease and, from a clinical stand point, at least three
breast cancer subtypes must be recognized: hormone-receptor
positive, HER-2 positive and triple negative. In particular, over-
expression of HER-2 oncogene occurs in 20–30% of the patients
with invasive breast cancer and is associated with poor prognosis
and decreased overall survival (Slamon et al, 1987). Retrospective
studies have shown that HER-2 overexpression is an independent
poor predictive factor of outcome after high-dose chemotherapy
both in high-risk and metastatic breast cancer (Bitran et al, 1996;
Kim et al, 2001; Nieto et al, 2002; Guarneri et al, 2004). Moreover,
Rodenhuis et al (2003) in the National Duch trial of high-dose
chemotherapy in high-risk breast cancer have reported an
unplanned subset analysis based on HER-2 status suggesting that
the improvement of relapse-free survival of high-dose chemo-
therapy in patients with stage II and III breast cancer and 10 or
more axillary nodes may be confined to patients with HER-2-
negative tumours. A part from its possible prognostic and
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spredictive role, the HER-2 status determines the choice of
treatment: when trastuzumab, a humanised monoclonal antibody
that selectively binds to the extracellular domain of the HER-2
protein, is used in combination with chemotherapy, response rate,
time to progression and median overall survival are improved
(Slamon et al, 2001; Marty et al, 2005). Unfortunately, Trastuzu-
mab was unexpectedly found to be associated with an increased
risk of cardiac dysfunctions and asymptomatic decrease in left
ventricular ejection fraction (LVEF); this risk was especially high
in patient receiving concurrent anthracyclines, older than 50 years
or with decreased LVEF after anthracyclines (Seidman et al, 2002;
Perez and Rodeheffer, 2004; Tan-Chiu et al, 2005).
In order to estimate the cardiac tolerability of trastuzumab after
high-dose chemotherapy, we have retrospective analysed the
clinical files of HER-2-positive breast cancer patients treated with
high-dose chemotherapy in the Italian Centers of the GITMO
group (Gruppo Italiano Trapianto Midollo Osseo).
PATIENTS AND METHODS
A questionnaire was sent to 11 major Italian centres. The following
information were requested: histology, hormonal receptor status,
HER-2 status (IHC or, if available, FISH status), radiation therapy
on cardiac area, previous chemotherapy with regimes including
anthracycline and paclitaxel, cumulative dose of anthracycline, use
of cardioprotective agents, status of disease at the time of high-
dose chemotherapy procedure, single or multiple transplant
procedure, dose of cyclophosphamide 44gm
 2 and mitoxantrone
460mgm
 2, status of disease after transplant, dose and schedule
of trastuzumab, cytotoxic agents associated with trastuzumab,
LVEF before starting trastuzumab and at the end of treatment, any
episode of congestive heart failure (CHF). Cardiac dysfunction was
defined as (1) a decline of LVEF X10% to below 50%, (2) a decline
of LVEF between 5 and 9% to below 50% with symptomatic
(NYHA class III–IV) CHF, (3) any symptomatic (NYHA class III–
IV) CHF event. Any one of the three criteria was sufficient to
confirm a diagnosis of cardiac dysfunction.
Statistical analysis
The Wilcoxon matched-pairs signed-ranks test was used to
determine if the distribution of the LVEF at baseline and at the
end of treatment was the same. Time to suspension and time to
cardiac event were calculated using the Kaplan–Meier method.
Time to suspension was calculated from the date of beginning of
the treatment with trastuzumab until the suspension or last follow-
up. Time to cardiac event was calculated from the date of
beginning of the treatment with trastuzumab until the date of the
cardiac event or last follow-up. The log-rank test was used to
compare the curves of time to cardiac event. The hazard ratio and
the 95% CI was calculated. The level of significance was set to be
0.05. The statistical software used for the analysis was STATA/SE
version 8.0.
RESULTS
All the centres returned the questionnaire and we could collect
data from 53 patients treated with trastuzumab for metastatic
disease between February 1999 and June 2005.
Patients characteristics are shown in Table 1. Median age was 47
years (range 29–66). Histology type was ductal carcinoma in 85%
of the patients; hormone receptor status was positive in 44.2% of
the patients. HER-2 expression was scored by immunohisto-
chemistry method as 3þ in 49 patients and as 2þ in four patients;
in the 2þ patients, HER-2 amplification was confirmed by FISH. A
total of 44 patients (83%) had received treatment with anthracy-
cline/paclitaxel-containing regimens and 16 patients (30%) had
received radiation therapy on cardiac area. Median cumulative
doses of doxorubicin or epidoxorubicin were 266mgm
 2 (range
60–500) and 395mgm
 2 (range 120–660), respectively. High-dose
chemotherapy was administered as adjuvant treatment to 17
patients, for locally advanced disease to three patients and for
metastatic disease to 33 patients. A total of 21 patients received a
single course of high-dose chemotherapy and 32 patients a double
course of high-dose chemotherapy. High-dose therapy included
melphalan–thiotepa in 27 patients (50.9%), mitoxantrone–
melphalan in 14 patients (26.4%), mitoxantrone–thiotepa in six
patients (11.3%), mitoxantrone–melphalan–thiotepa in three
patients (5.7%); three patients (5.7%) received other regimens.
Median interval between high-dose chemotherapy and the begin-
ning of trastuzumab was 6 months (range 0–90). Trastuzumab was
administered at weekly or 3-weekly schedule in 33 and 20 patients,
respectively. Trastuzumab was given as single agent in 17 patients,
in combination with paclitaxel in 21 patients, and with vinorelbine
in 15 patients. Median duration of treatment with trastuzumab was
11 months (1–46) with 32 patients receiving trastuzumab for more
than 12 months. At the time of analysis, 41 patients have stopped
the treatment with trastuzumab: seven for cardiac toxicity, 29 for
progression of disease, four for patient’s decision, one patient died
early after the administration of trastuzumab; 12 patients are still
on treatment.
Cardiac dysfunction
Baseline LVEF was available for all patients; LVEF at the end of
treatment was available for 28 patients and 13 patients had also a
third measurement of LVEF. Median LVEF values at baseline and
Table 1 Characteristics of the patients
47 years (29–66)
Age: median (range) No. of patients %
Histology type
Ductal carcinoma 45 85
Lobular carcinoma 8 15
Hormone receptor status
ER and/or PgR+ 23 43.4
HER-2 status
2+ (FISH positive) 4 7. 5
3+ 49 92.5
Radiation therapy on cardiac area 16 30.2
Prior anthracycline/paclitaxel 44 83.0
HDCT
Adjuvant treatment 17 32.1
For metastatic disease 33 62.3
For locally advanced disease 3 5.7
Single course of HDCT 21 39.6
Multiple courses of HDCT 32 60.4
HDCT with CTX44gm
 2 37 69.8
HDCT with DHAD 460mgm
 2 16 30.2
Dose of trastuzumab
6mgkg
 13 weekly
 1 20 37.7
2mg
 1kgweekly
 1 33 62.3
Trastuzumab
Single agent 17 32.1
With paclitaxel 21 39.6
With vinorelbine 15 28.3
CTX¼cyclophosphamide; DHAD¼mitoxantron; ER¼estrogen receptor;
PgR¼progesteron receptor; FISH¼fluorescence in situ hybridisation.
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sat the end of trastuzumab were 60.5% (43–72) and 55% (25–72),
respectively (Figure 1); this difference resulted statistically
significant with a P-value of 0.01. At the end of treatment with
trastuzumab, seven patients (25%) had a reduction of LVEF to less
than 50%. In this group of patients, one patient had a decline of
LVEF of 3% without cardiac symptoms, one patients had a
reduction of LVEF of 7% and developed mild cardiac symptoms
classified as NYHA class II, five patients had a decline of LVEF
X10% and two of these developed congestive heart failure
classified as NYHA class III. According to our definition, five
out of 28 patients with evaluable LVEF experienced a cardiac event
(17.9%).
On the entire group of patients, two out of 53 (3.8%) developed a
congestive heart failure (NYHA class III). Both patients had a
decline of LVEF 410% to below 50%. These two patients started
trastuzumab within 2 months from high-dose chemotherapy and
the duration of treatment with trastuzumab was 18 and 46 months,
respectively. One of these two patients had previously received
doxorubicin (cumulative dose of 300mgm
 2).
Trastuzumab was discontinued in seven patients with a
LVEFo50%. Follow-up data for cardiac function recovery are
available for four patients only: all these patients recovered a
normal LVEF at a median interval of 11 months (range 3–19).
Analysis of risk factors
The incidence of cardiac dysfunction was analysed according to
risk factors including age, baseline LVEF, previous radiation
therapy on cardiac area, single vs multiple transplant, dose of
cyclophosphamide and mitoxantrone, previous anthracycline
exposure and duration of treatment with Trastuzumab (Table 2).
Age X50 years was the only factor significantly associated with
cardiac dysfunction (P: 0.027). Moreover, we have analysed risk
factors associated with a significant decline of LVEF at the end of
treatment with trastuzumab (Table 3). Age X50 years and multiple
courses of high-dose chemotherapy were associated with a 13%
reduction in LVEF (P¼0.02) and a 4% reduction in LVEF
(P¼0.02), respectively.
Baseline LVEFo55%, previous treatment with anthracicline/
paclitaxel, high-dose of cyclophospamide alone or in combination
with high-dose mitoxantrone and duration of treatment with
trastuzumab 412 months were not associated with a significant
reduction of LVEF. Previous radiation therapy on cardiac area was
associated with a 4% reduction of LVEF, but this value did not
reach the statistical significance (0.08).
DISCUSSION
Several studies have shown that high-dose chemotherapy is not
able to modify the poorer prognosis of HER-2-positive breast
cancer patients (Slamon et al, 1987; Bitran et al, 1996; Nieto et al,
2002; Rodenhuis et al, 2003; Guarneri et al, 2004). It is therefore
clear that these patients should be treated with trastuzumab.
Unfortunately, very few data on the cardiac tolerability of
trastuzumab after high-dose chemotherapy are available.
A retrospective analysis on 1219 patients treated for metastatic
disease with standard chemotherapy with or without trastuzumab
in seven phase II and III clinical trials showed symptomatic
cardiac dysfunction (NYHA class III–IV) in 2–16% of patients
who received trastuzumab. The incidence was 2–4% for patients
receiving first-line trastuzumab as single agent or in combination
with paclitaxel, while it increased to 16% for patients receiving
trastuzumab plus doxorubicin–cyclophosphamide combination.
The overall cardiac dysfunction rate was 13 and 27% for patients
receiving trastuzumab plus paclitaxel or trastuzumab plus
doxorubicin–cyclophosphamide (AC) combination, respectively.
Analysis of potential risk factors for cardiac dysfunction in
patients with metastatic breast cancer treated with standard-dose
chemotherapy plus trastuzumab has demonstrated that increasing
age and the association of trastuzumab plus anthracycline was a
statistically significant predictive factor. Other factors such as
prior radiotherapy, and mean cumulative dose of doxorubicin
were not found to be independent predictive factors of cardiac
dysfunction (Seidman et al, 2002). Moreover, Perez and Rodeheffer
(2004) reviewed data from new prospective clinical trials reporting
lower incidence of trastuzumab-related cardiac toxicity when more
stringent patient selection and cardiac monitoring criteria were
adopted. More recently, Tan-Chiu et al (2005) reported data on
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Figure 1 Values and median of LVEF at baseline and at the end of
treatment with trastuzumab.
Table 2 Potential risk factors for cardiac dysfunction (28 patients, five
events)
No. of
patients
No. of
events
HR (95%
CI) P-value
RT on cardiac area
No 18 3
Yes 10 2 0.68 (0.07;6.7) 0.74
HDCT
Single 8 1
Multiple 20 4 1.22 (0.08;7.99) 0.87
High-dose agents
No CTX-no DHAD 4 1
CTX 13 1 0.19 (0.01;3.25) 0.45
CTX+DHAD 11 3 0.47 (0.04;6.23)
Anthracicline
No 4 2
Yes 24 3 0.52 (0.05;5.05) 0.56
Trastuzumab
p12 months 17 2
412months 11 3 0.39 (0.03;4.58) 0.43
Age (years)
o50 19 1
X50 9 4 8.79(0.88;88.08) 0.03
LVEF baseline%
X55 21 4
o55 7 1 0.71 (0.07;6.91) 0.76
CTX¼cyclophosphamide; DHAD¼mitoxantron; LVEF¼left ventricular ejection
fraction; HR¼hazard ratio. P-value: log rank test for time to cardiac dysfunction.
RT¼radiation therapy.
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scardiac dysfunction associated to herceptin in combination with
paclitaxel following AC regimen in high-risk breast cancer. The
incidence of CHF was 4.1%. Age X50 years and baseline
LVEFo55% were found as risk factors significantly associated
with CHF.
Cardiotoxicity is also a major concern in the treatment
with high-dose chemotherapy. Risk factors for cardiotoxicity
include high-dose cyclophosphamide, high-dose mitoxantrone
and previous radiation therapy on cardiac area (Morandi et al,
2005). Several studies failed to demonstrated a relationship
between previous anthracycline exposure and development of
cardiac toxicity following high-dose chemotherapy (Nieto et al,
2000; Petros et al, 2002). However, we and others have reported
that high-dose alkylating agents in metastatic breast
cancer patients previously exposed to cumulative dose of
epirubicin X450mgm
 2 is associated with a 4–5% of congestive
heart failure rate (Alidina et al, 1999; Gennari et al, 1999; Bengala
et al, 2001). Moreover, we have shown that a double course of
high-dose chemotherapy after anthracycline-containing regimen
in patients of metastatic breast cancer can induce a transient
decline of LVEF to less than 50% in 14.3% of the patients (Bengala
et al, 2003).
Our retrospective analysis shows that median LVEF is
significantly lower after trastuzumab in patients previously treated
with high-dose chemotherapy; moreover, in these patients, cardiac
dysfunction rate and symptomatic cardiac failure (NYHA class III)
rate were 17.9 and 3.8%, respectively. The incidence of CD was
higher than that reported with trastuzumab as single agent or in
combination with paclitaxel but not superior to that observed with
trastuzumab administered concomitantly with anthracyclines. Age
450 years and multiple transplant procedures have been the only
factors associated with an increased risk of cardiotoxicity.
Interestingly, 83% of our patients had received anthracycline–
taxane chemotherapy, another potentially cardiotoxic regimen,
before HD treatment; moreover, duration of trastuzumab treat-
ment was relatively long (median 11 months), with 32 patients
treated for more than 1 year.
Nieto et al (2004) and Goncalves et al (2005) have prospectively
studied the feasibility of the concurrent administration of
trastuzumab with alkylator-based high-dose chemotherapy in
breast cancer. End points of the studies were safety and
pharmacokinetic profile evaluation. Trastuzumab was adminis-
tered for a median of 9 weeks (range 9–48) and 15 weeks (range
1–39) in the two trials with no apparent increased toxicity and in
particular cardiac dysfunction.
In conclusion, our retrospective analysis shows that the
administration of trastuzumab after high-dose chemotherapy is
feasible with an incidence of cardiac dysfunction and symptomatic
cardiac failure not superior to that reported with trastuzumab in
combination with anthracyclines. Age X50 years, multiple courses
of high-dose chemotherapy and prior radiation therapy on cardiac
area are risk factors for cardiac dysfunction in this patient
population.
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